Browse

You are looking at 1 - 10 of 15 items for :

  • Kidney transplantation x
  • Refine by Content Type: All x
Clear All Modify Search

A team of surgeons at NYU Langone Health in New York have transplanted a pig kidney into a human patient without triggering immediate rejection by the recipient’s immune system.

Priority #2: TRANSFORM TRANSPLANT and increase access to donor kidneys. If patients understood the benefits of transplantation and the process involved, more would likely accept the opportunity and pursue transplant listing.

ASN applauds the U.S. Food and Drug Administration for amending the emergency use authorizations for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, including kidney transplant recipients. 

Investigators discovered that kidney failure symptoms tended to increase or remain unchanged between transplant evaluation and transplantation; however, three months after transplantation, 9 of 11 symptoms lessened.

Reaffirming that race is a social, not a biological, construct, ASN remains committed to ensuring that racial and ethnic biases do not affect the diagnosis and treatment of kidney diseases.

Taking part in the 9th Annual Kidney Health Advocacy Day, advocates from the American Association of Kidney Patients (AAKP) and ASN are urging their congressional delegations to increase funding for kidney research at the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) to drive new breakthroughs for kidney patients and study the impact of COVID-19 on kidney health and people with kidney diseases.

Advocates from the American Association of Kidney Patients (AAKP) and ASN are calling on Congress to include funding for KidneyX in its annual government funding legislation and advance innovative technologies for kidney patients, such as a wearable or implantable artificial kidney.

Kidney transplantation saves lives. For many people with kidney failure, transplant offers longer survival, greater quality of life, and lower associated costs compared to dialysis.

 

Today the US Senate passed the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act, extending Medicare coverage of life saving immunosuppressive medications for the life of the kidney transplant. This welcome advance will take effect in 2023.

This tremendous advance results from countless hours of advocacy by ASN members and stakeholders throughout the kidney and transplant communities

Bipartisan bill has been ASN's top legislative priority since 2009

Congress is passing the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act as part of priority year-end package.

This legislation extends Medicare coverage of live-saving immunosuppressive medications for kidney transplant patients for the life of the kidney transplant. Currently coverage is restricted to 36 months post transplant: patients who cannot obtain private coverage and are unable to afford the medications lose their transplanted kidney and return to dialysis. About 375 people annually are estimated to lose their kidney transplant because they cannot afford immunosuppressives.